Vorobyeva N M
Federal State Budgetary Educational Institution of Higher Education, "Pirogov Russian National Research Medical University " of the Ministry of Health of the Russian Federation, "Russian Gerontology Clinical Research Center".
Kardiologiia. 2018 Feb(2):91-104. doi: 10.18087/cardio.2018.2.10091.
The article contains an outline of the 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. This document considers in detail problems of necessity and safety of temporary interrupting of anticoagulation for the period of procedure, main principles of interruption and restarting anticoagulant therapy after procedure, indications to the transitional (bridging) therapy in the periprocedural period, as well as possible strategies of periprocedural management of patients in dependence of risk of bleeding and thromboembolic complications. This Expert Consensus Decision Pathway refer to the periprocedural use of both oral (vitamin K antagonists, new oral anticoagulants) and parenteral (unfractionated and low-molecular-weight heparins) anticoagulants.
本文包含2017年美国心脏病学会（ACC）非瓣膜性心房颤动患者围手术期抗凝管理专家共识决策路径概述。该文件详细探讨了手术期间临时中断抗凝治疗的必要性和安全性问题、术后抗凝治疗中断和重新开始的主要原则、围手术期过渡（桥接）治疗的适应症，以及根据出血和血栓栓塞并发症风险对患者进行围手术期管理的可能策略。本专家共识决策路径涉及口服（维生素K拮抗剂、新型口服抗凝药）和肠外（普通肝素和低分子肝素）抗凝药在围手术期的使用。
